BioLargo Initiates Alpha Testing of Verralize's Portable PFAS Test Kit to Validate Performance for Future Commercialization

Stock Information for Revance Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Revance Therapeutics Inc.

BioLargo Provides Review of 2025 Accomplishments and Insights for Coming Year
BioLargo Announces Results of 2025 Annual Stockholder Meeting
Independent Evaluation Confirms Breakthrough Performance of BioLargo's Cellinity Battery Technology for Grid-Scale Energy Storage
Sidoti Events, LLC's Virtual May Micro-Cap Conference
BioLargo Q1 2025 Earnings Results Webcast and Conference Call on Thursday, May 15, 2025 - 4:30 PM Eastern Time
BioLargo Subsidiary Clyra Medical Advances Product Distribution Through a Series of Agreements
BioLargo's PFAS Solution Provides Dramatic Long-Term Cost Savings Compared with Incumbent Technologies
AI & Technology Virtual Investor Conference: Presentations Now Available for Online Viewing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.